Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
SGLT2 Inhibitors in Acute Heart Failure
Author(s): Hugo Prado-Prado , Sergio Raposeiras-Roubín Added: 2 months ago

Heart Failure
30th Annual Meeting of the ISCP
Author(s): Daryl Dakay , Marion Patricio Added: 1 month ago

Prevention & Chronic Conditions

Heart Failure
Oral P2Y12 Inhibitors and Drug Interactions
Author(s): Elisabetta Bigagli , Jacopo Angelini , Alessandro Mugelli , et al Added: 11 months ago

Anticoagulation

Prevention & Chronic Conditions
Factor XIa Inhibitors’ Future Position in AF
Author(s): Maki Komiyama , Moritake Iguchi , Hiromichi Wada , et al Added: 1 year ago

Anticoagulation
Early SGLT2i/MRA Use Benefits Suspected HF Patients
Added: 2 months ago Source:  Cardiac Failure Review Journal
Delays in diagnosis and treatment for patients with suspected heart failure (HF) in the community can lead to preventable hospitalisations and deaths. A new modelling study by Dr Kieran Docherty and colleagues suggests that early initiation of disease-modifying therapies in select patients at the time of an elevated natriuretic peptide test could significantly reduce these adverse outcomes… View more

Intervention

Heart Failure
30th Annual Meeting of the ISCP
Author(s): Alberto Alen Andrés , María Salgado , Maria Fernández García , et al Added: 1 month ago

Prevention & Chronic Conditions

Heart Failure
AHA 25: The CORALreef HeFH Trial
Author(s): Christie Ballantyne Added: 6 months ago
AHA Scientific Sessions 2025 - Dr Christie Ballantyne (Baylor College of Medicine, Houston, TX, US) discusses findings from the CORALreef HeFH trial, examining the efficacy and safety of enlicitide decanoate, an oral PCSK9 inhibitor, in adults with heterozygous familial hypercholesterolemia.This Phase 3, randomized, double-blind, placebo-controlled study evaluated 303 participants with… View more

Cardiovascular Kidney Metabolic
Enlicitide: Oral PCSK9 Inhibitor Lowers LDL-C by 56%
Added: 2 months ago Source:  Radcliffe Cardiology
Written by Mirjam Boros, Radcliffe CardiologyA new oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, enlicitide, has demonstrated a significant reduction in low-density lipoprotein cholesterol (LDL-C) levels in patients with or at risk of atherosclerotic cardiovascular disease (ASCVD), according to results from the CORALreef Lipids trial.¹Mechanism of ActionEnlicitide is an… View more

Cardiovascular Kidney Metabolic

Prevention & Chronic Conditions
Author(s): Byoung Geol Choi , Seung-Woon Rha , Se Yeon Choi , et al Added: 1 year ago

Anticoagulation
AHA 24: The EMPEROR-Preserved Trial
Author(s): Andrew JS Coats Added: 1 year ago
AHA Conference 2024 - Discover the findings from a new study on the impact of diastolic dysfunction on the efficacy of empagliflozin in heart failure in the EMPEROR-Preserved trial.Prof Andrew Coats (Heart Research Institute, New South Wales, AU) joins us onsite at AHA Conference to discuss findings from a new analysis of diastolic dysfunction in the EMPEROR-Preserved trial (NCT03057951).EMPEROR… View more

Heart Failure